secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2025-03-07T23:59:59+00:00
Accession:  0001213900-25-021738
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial Pharma receives Nasdaq bid price deficiency notice; compliance deadline Sept 1, 2025
--------------------------------------------------------------------------------

- Received Nasdaq notice March 5, 2025 for failing minimum bid price of $1.00 for 30 consecutive business days (Jan 17 - Mar 4, 2025).
- No immediate effect on listing or trading; common stock continues on Nasdaq Capital Market under symbol ADIL.
- Company has until September 1, 2025 (180 days) to regain compliance by achieving $1.00 closing bid for 10 consecutive days.
- If noncompliant by Sept 1, Company may be eligible for additional 180-day period if meets other listing standards.
- Company considering available options, including a reverse stock split, to cure the bid price deficiency.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390025021738/0001213900-25-021738-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390025021738/ea0233491-8k_adial.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-021738

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer